Gene expression profile of human thyroid cancer in relation to its mutational status

Journal of Molecular Endocrinology

Volumn 47, Issue 3, 2011, Pages

  Rusinek, Dagmara ^a   Sylwia Ulczok, Sylwia ^a   Jarzab, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR PAX8;

ANAPLASTIC CARCINOMA; CARCINOGENESIS; GENE EXPRESSION PROFILING; HUMAN; MUTATION; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

GENE EXPRESSION PROFILING; HUMANS; MUTATION; THYROID NEOPLASMS; TRANSCRIPTOME;

EID: 84856353764     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0023     Document Type: Review

References (131)

1. Abrosimov A, Saenko V, Rogounovitch T, Namba H, Lushnikov E, Mitsutake N & Yamashita S 2007 Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. International Journal of Cancer 120 196-200. (doi:10. 1002/ijc.22290)
2. Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, Guenther SM, O'Leary JJ & Sheils OM 2008 Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Molecular Cancer 7 89. (doi:10.1186/1476-4598-7-89)
3. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C et al. 2003 Caveolin-1 and caveolin-2 together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors downregulated in sporadic follicular thyroid carcinogenesis. Cancer Research 63 2864-2871.
4. Aratake Y, Marutsuka K, Kiyoyama K, Kuribayashi T, Miyamoto T, Yakushiji K, Ohno S, Miyake Y, Sakaguchi T, Kobayashi TK et al. 2010 EMMPRIN (CD147) expression and differentiation of papillary thyroid carcinoma: implications for immunocytochemistry in FNA cytology. Cytopathology 21 103-110. (doi:10.1111/j.1365-2303.2009. 00716.x)
5. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA & Fahey TJ III 2003 Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clinical Cancer Research 9 1792-1800.
6. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R et al. 2005 Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene 24 4155-4161. (doi:10.1038/sj.onc.1208578)
7. Borup R, Rossing M, Henao R, Yamamoto Y, Krogdahl A, Godballe C, Winther O, Kiss K, Christensen L, Hogdall E et al. 2010 Molecular signatures of thyroid follicular neoplasia. Endocrine-Related Cancer 17 691-708. (doi:10.1677/ERC-09-0288)
8. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, Shioda T, Roberts AB & Lechleider RJ 2000 The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. Journal of Biological Chemistry 275 2115-2122. (doi:10.1074/jbc.275.3.2115)
9. Cahill S, Smyth P, Denning K, Flavin R, Li J, Potratz A, Guenther SM, Henfrey R, O'Leary JJ & Sheils O 2007 Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Molecular Cancer 6 21. (doi:10. 1186/1476-4598-6-21)
10. Carter SL, Eklund AC, Kohane IS, Harris LN & Szallasi Z 2006 A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nature Genetics 38 1043-1048. (doi:10.1038/ng1861)
11. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P et al. 2006 PAX8-PPAR gamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 213-220. (doi:10.1210/jc. 2005-1336)
12. Cerutti JM 2007 Nodule diagnosed as follicular patterned lesion: are biomarkers the promise? Arquivos Brasileiros de Endocrinologia e Metabologia 51 832-842. (doi:10.1590/S0004-27302007000500022)
13. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM & Kimura ET 2003 Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. Journal of Endocrinological Investigation 26 516-521.
14. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J & Riggins GJ 2004 A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. Journal of Clinical Investigation 113 1234-1242. (doi:10.1172/JCI19617)
15. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC & Liu RT 2010 miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20 489-494. (doi:10.1089/thy.2009.0027)
16. Di Cristofaro J, Marcy M, Vasko V, Sebag F, Fakhry N, Wynford-Thomas D & de Micco C 2006 Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Human Pathology 37 824-830. (doi:10.1016/j.humpath.2006.01. 030)
17. Donghi R, Longoni A, Pilotti S, Michieli P, Della PG & Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 91 1753-1760. (doi:10.1172/JCI116385)
18. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A et al. 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. Journal of Clinical Endocrinology and Metabolism 92 2840-2843. (doi:10.1210/jc.2006-2707)
19. Ensinger C, Kremser R, Prommegger R, Spizzo G & Schmid KW 2006 EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. Journal of Immunotherapy 29 569-573. (doi:10. 1097/01.cji.0000211303.52503.da)
20. Espadinha C, Pinto AE & Leite V 2009a Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. Oncology Reports 22 907-913. (doi:10.3892/or_00000516)
21. Espadinha C, Santos JR, Sobrinho LG & Bugalho MJ 2009b Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency. Clinical Endocrinology 70 629-635. (doi:10.1111/j.1365-2265.2008.03376.x)
22. Estep AL, Palmer C, McCormick F & Rauen KA 2007 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2 e1279. (doi:10.1371/journal. pone.0001279)
23. Eszlinger M & Paschke R 2010 Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Molecular and Cellular Endocrinology 322 29-37. (doi:10.1016/j.mce.2010.01.010)
24. Eszlinger M, Krohn K, Kukulska A, Jarzab B & Paschke R 2007 Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews 28 322-338. (doi:10. 1210/er.2006-0047)
25. Fagin JA 2005 Genetics of papillary thyroid cancer initiation: implications for therapy. Transactions of the American Clinical and Climatological Association 116 259-269.
26. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184. (doi:10.1172/JCI116168)
27. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ & van den Brule AJ 2010 The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Annals of Oncology 21 2396-2402. (doi:10.1093/annonc/mdq258)
28. Finley DJ, Zhu B, Barden CB & Fahey TJ III 2004a Discrimination of benign and malignant thyroid nodules by molecular profiling. Annals of Surgery 240 425-436. (doi:10.1097/01.sla.0000137128. 64978.bc)
29. Finley DJ, Zhu B & Fahey TJ III 2004b Molecular analysis of Hurthle cell neoplasms by gene profiling. Surgery 136 1160-1168. (doi:10. 1016/j.surg.2004.05.061)
30. Fluge O, Bruland O, Akslen LA, Lillehaug JR & Varhaug JE 2006 Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16 161-175. (doi:10.1089/thy.2006.16.161)
31. Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M et al. 2009 Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid 19 247-255. (doi:10.1089/thy. 2008.0235)
32. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F et al. 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocrine-Related Cancer 15 191-205. (doi:10.1677/ERC-07-0212)
33. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440. (doi:10.1038/sj.onc.1207980)
34. Fujarewicz K, Jarzab M, Eszlinger M, Krohn K, Paschke R, Oczko-Wojciechowska M, Wiench M, Kukulska A, Jarzab B & Swierniak A 2007 A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocrine-Related Cancer 14 809-826. (doi:10.1677/ERC-06-0048)
35. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML & Rimm DL 1999 Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Research 59 1811-1815.
36. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G 2003 Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 21 3226-3235. (doi:10. 1200/JCO.2003.10.130)
37. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 65 10199-10207. (doi:10.1158/0008-5472. CAN-04-4259)
38. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656. (doi:10. 1038/sj.onc.1208822)
39. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z et al. 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clinical Cancer Research 12 1983-1993. (doi:10.1158/ 1078-0432.CCR-05-2039)
40. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH & Nagtegaal ID 2007 Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Modern Pathology 20 221-232. (doi:10. 1038/modpathol.3800733)
41. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G & Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Research 28 305-308.
42. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 557-563. (doi:10.1016/0092-8674(90)90659-3)
43. Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO & Coats S 1999 Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Molecular and Cellular Biology 19 612-622.
44. Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F & Santoro M 2005 Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 90 4703-4709. (doi:10.1210/jc.2004-2459)
45. Handkiewicz-Junak D, Czarniecka A & Jarzab B 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Molecular and Cellular Endocrinology 322 8-28. (doi:10.1016/j.mce.2010.01.007)
46. Hara E, Okamoto S, Nakada S, Taya Y, Sekiya S & Oda K 1993 Protein phosphorylation required for the formation of E2F complexes regulates N-myc transcription during differentiation of human embryonal carcinoma cells. Oncogene 8 1023-1032.
47. Hinsch N, Frank M, Doring C, Vorlander C & Hansmann ML 2009 QPRT: a potential marker for follicular thyroid carcinoma including minimal invasive variant; a gene expression, RNA and immunohistochemical study. BMC Cancer 9 93. (doi:10.1186/1471-2407-9-93)
48. Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C et al. 2011 Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R): a GEMCAD study. Cancer Biology&Therapy 11 177-183. (doi:10.4161/ cbt.11.2.13839)
49. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170. (doi:10.1158/ 1078-0432.CCR-06-1125)
50. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C et al. 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. PNAS 98 15044-15049. (doi:10.1073/pnas.251547398)
51. Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T et al. 2009 S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Research 29 4157-4161.
52. Jakubowski M & Hunt JL 2009 BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. American Journal of Surgical Pathology 33 1590-1593. (doi:10.1097/ PAS.0b013e3181b7c7ae)
53. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D et al. 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Research 65 1587-1597. (doi:10.1158/0008-5472.CAN-04-3078)
54. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK et al. 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 3667-3670. (doi:10.1210/jc.2005-2836)
55. Jurek A, Heldin CH & Lennartsson J 2011 Platelet-derived growth factor-induced signaling pathways interconnect to regulate the temporal pattern of Erk1/2 phosphorylation. Cellular Signalling 23 280-287. (doi:10.1016/j.cellsig.2010.09.013)
56. Karim R, Tse G, Putti T, Scolyer R & Lee S 2004 The significance of the Wnt pathway in the pathology of human cancers. Pathology 36 120-128. (doi:10.1080/00313020410001671957)
57. Kim YW, Do IG & Park YK 2006 Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathology, Research and Practice 202 759-765. (doi:10.1016/j.prp.2006. 07.006)
58. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457.
59. Klopfleisch R, Lenze D, Hummel M & Gruber AD 2011 The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Veterinary Journal (In Press). (doi:10.1016/j. tvjl.2010.10.018)
60. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G & Fagin JA 2006 Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. Journal of Biological Chemistry 281 3800-3809. (doi:10. 1074/jbc.M511690200)
61. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306. (doi:10. 1038/nrc1836)
62. Kouniavsky G & Zeiger MA 2010 Thyroid tumorigenesis andmolecular markers in thyroid cancer. Current Opinion in Oncology 22 23-29. (doi:10.1097/CCO.0b013e328333846f)
63. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M & Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPAR gamma 1 rearrangement display characteristic genetic alterations. American Journal of Pathology 167 223-231. (doi:10.1016/S0002-9440(10)62967-7)
64. La Perle KM, Jhiang SM & Capen CC 2000 Loss of p53 promotes anaplasia and local invasion in RET/PTC1-induced thyroid carcinomas. American Journal of Pathology 157 671-677. (doi:10. 1016/S0002-9440(10)64577-4)
65. La Thangue NB & Rigby PW 1987 An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 49 507-513. (doi:10. 1016/0092-8674(87)90453-3)
66. Lavra L, Ulivieri A, Rinaldo C, Dominici R, Volante M, Luciani E, Bartolazzi A, Frasca F, Soddu S & Sciacchitano S 2009 Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas. Journal of Pathology 218 66-75. (doi:10.1002/path.2510)
67. Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, Clifton-Bligh R, Staaf J, Borg A, Delbridge L, Robinson BG et al. 2008 Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocrine-Related Cancer 15 801-815. (doi:10.1677/ERC-08-0018)
68. Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP et al. 2003 SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. PNAS 100 8412-8417. (doi:10.1073/pnas.1430846100)
69. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ & Warnaar SO 1994 Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. Journal of Cell Biology 125 437-446. (doi:10. 1083/jcb.125.2.437)
70. Maenhaut C, Detours V, Dom G, Handkiewicz-Junak D, Oczko-Wojciechowska M & Jarzab B 2011 Gene expression profiles for radiation-induced thyroid cancer. Clinical Oncology 23 282-288. (doi:10.1016/j.clon.2011.01.509)
71. Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, Vigneri P, Aloisi A, Vigneri R & Frasca F 2005 The p53-homologue p63 may promote thyroid cancer progression. Endocrine-Related Cancer 12 953-971. (doi:10.1677/erc.1. 00968)
72. Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, Fujioka Y & Kamma H 2008 Decreased expression of the thyroidstimulating hormone receptor in poorly-differentiated carcinoma of the thyroid. Oncology Reports 19 1405-1411.
73. Melamed D, Tiefenbrun N, Yarden A & Kimchi A 1993 Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells. Molecular and Cellular Biology 13 5255-5265.
74. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 66 6521-6529. (doi:10.1158/0008-5472.CAN-06-0739)
75. Mishra A, Agrawal V, Krishnani N & Mishra SK 2009 Prevalence of RET/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population. Journal of Postgraduate Medicine 55 171-175. (doi:10.4103/0022-3859. 57390)
76. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M & Ringel MD 2004 Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Molecular Carcinogenesis 41 98-107. (doi:10.1002/mc.20042)
77. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N, Montaner D, Matias-Guiu X, Dopazo J, de Leiva A et al. 2008 Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27 1554-1561. (doi:10.1038/ sj.onc.1210792)
78. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA & Lloyd RV 2005 RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Laboratory Investigation 85 1065-1075. (doi:10.1038/labinvest. 3700306)
79. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G & Santoro M 2009 Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Research 69 1916-1923. (doi:10.1158/0008-5472.CAN-08-1693)
80. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003a BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404. (doi:10.1210/jc.2003-030838)
81. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, Kroll TG & Nikiforov YE 2003b RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. Journal of Clinical Endocrinology and Metabolism 88 2318-2326. (doi:10.1210/jc.2002-021907)
82. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf (V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
83. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ & Cerutti JM 2008 Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clinical Cancer Research 14 4735-4742. (doi:10.1158/1078-0432.CCR-07-4372)
84. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, Mizutani K, Shimizu K, Nagahama M, Ito K et al. 2004 Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocrine-Related Cancer 11 843-854. (doi:10.1677/erc.1.00818)
85. Pita JM, Banito A, Cavaco BM & Leite V 2009 Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. British Journal of Cancer 101 1782-1791. (doi:10. 1038/sj.bjc.6605340)
86. Placzkowski KA, Reddi HV, Grebe SK, Eberhardt NL & McIver B 2008 The Role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Research 2008 672829. (doi:10.1155/2008/672829)
87. Polanski A, Polanska J, Jarzab M, Wiench M & Jarzab B 2007 Application of Bayesian networks for inferring cause-effect relations from gene expression profiles of cancer versus normal cells. Mathematical Biosciences 209 528-546. (doi:10.1016/j.mbs.2007.03. 006)
88. Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix JL, Bournaud C, Orgiazzi J et al. 2005 Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 90 3028-3035. (doi:10.1210/jc. 2004-1394)
89. Powell DJ Jr, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A et al. 1998 The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Research 58 5523-5528.
90. Prasad ML, Pellegata NS, Kloos RT, Barbacioru C, Huang Y & de la Chapelle A 2004 CITED1 protein expression suggests papillary thyroid carcinoma in high throughput tissue microarray-based study. Thyroid 14 169-175. (doi:10.1089/105072504773297830)
91. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M et al. 2008 Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research 68 9375-9383. (doi:10.1158/0008-5472. CAN-08-2223)
92. Puxeddu E & Moretti S 2007 Clinical prognosis in BRAF-mutated PTC. Arquivos Brasileiros de Endocrinologia e Metabologia 51 736-747. (doi:10.1590/S0004-27302007000500011)
93. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D & Klugbauer S 2000 Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clinical Cancer Research 6 1093-1103.
94. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A & Chinnaiyan AM 2004 Large-scale metaanalysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. PNAS 101 9309-9314. (doi:10.1073/pnas.0401994101)
95. Riesco-Eizaguirre G & Santisteban P 2007 New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocrine-Related Cancer 14 957-977. (doi:10.1677/ERC-07-0085)
96. Riesco-Eizaguirre G, Rodriguez I, De la Vieja V, Costamagna E, Carrasco N, Nistal M & Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Research 69 8317-8325. (doi:10.1158/0008-5472.CAN-09-1248)
97. Rodrigues R, Roque L, Espadinha C, Pinto A, Domingues R, Dinis J, Catarino A, Pereira T & Leite V 2007a Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncology Reports 18 917-926.
98. Rodrigues RF, Roque L, Krug T & Leite V 2007b Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. British Journal of Cancer 96 1237-1245. (doi:10.1038/sj.bjc.6603578)
99. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A et al. 2008 BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocrine-Related Cancer 15 511-520. (doi:10.1677/ERC-07-0130)
100. Saltman B, Singh B, Hedvat CV, Wreesmann VB & Ghossein R 2006 Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140 899-905. (doi:10.1016/j.surg.2006.07.027)
101. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM et al. 2007 A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 67 10148-10158. (doi:10.1158/0008-5472.CAN-07-1887)
102. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G & Fusco A 1994 Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 509-516.
103. Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A et al. 2002 RET activation and clinicopathologic features in poorly differentiated thyroid tumors. Journal of Clinical Endocrinology and Metabolism 87 370-379. (doi:10.1210/jc.87.1.370)
104. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS et al. 2010 Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Research 70 512-519. (doi:10.1158/0008-5472.CAN-09-1851)
105. Schwartzenberg-Bar-Yoseph F, Armoni M & Karnieli E 2004 The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Research 64 2627-2633. (doi:10. 1158/0008-5472.CAN-03-0846)
106. Scrideli CA, Carlotti CG Jr, Okamoto OK, Andrade VS, Cortez MA, Motta FJ, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo SM et al. 2008 Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. Journal of Neuro-Oncology 88 281-291. (doi:10.1007/s11060-008-9579-4)
107. Sheu SY, Grabellus F, Schwertheim S, Handke S, Worm K & Schmid KW 2009 Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Hormone and Metabolic Research 41 482-487. (doi:10.1055/s-0029-1215558)
108. Soares P & Sobrinho-Simoes M 2011 Cancer: small papillary thyroid cancers-is BRAF of prognostic value? Nature Reviews. Endocrinology 7 9-10. (doi:10.1038/nrendo.2010.213)
109. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R et al. 2004 High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Research and Treatment 86 207-213. (doi:10. 1023/B:BREA.0000036787.59816.01)
110. Tabach Y, Milyavsky M, Shats I, Brosh R, Zuk O, Yitzhaky A, Mantovani R, Domany E, Rotter V & Pilpel Y 2005 The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. Molecular Systems Biology 1 2005. (doi:10.1038/msb4100030)
111. Takano T, Matsuzuka F, Miyauchi A, Yokozawa T, Liu G, Morita S, Kuma K & Amino N 1998 Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study. British Journal of Cancer 78 221-224. (doi:10.1038/bjc.1998.468)
112. Terrile M, Appolloni I, Calzolari F, Perris R, Tutucci E & Malatesta P 2010 PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer 10 550. (doi:10.1186/1471-2407-10-550)
113. Thomas NE 2006 BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Research 16 97-103. (doi:10.1097/ 01.cmr.0000215035.38436.87)
114. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF & de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 2745-2752. (doi:10.1210/jc.2002-021186)
115. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A et al. 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. PNAS 104 2803-2808. (doi:10.1073/pnas.0610733104)
116. Visconti R, Federico A, Coppola V, Pentimalli F, Berlingieri MT, Pallante P, Kruhoffer M, Orntoft TF & Fusco A 2007 Transcriptional profile of Ki-Ras-induced transformation of thyroid cells. Cancer Investigation 25 256-266. (doi:10.1080/07357900701206406)
117. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E et al. 2007 Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 7590-7595. (doi:10.1038/sj.onc.1210564)
118. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M & Nikiforov YE 2009 RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. Journal of Clinical Endocrinology and Metabolism 94 4735-4741. (doi:10.1210/jc.2009-1233)
119. Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y et al. 2008 Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and overexpression of platelet-derived growth factor-B in papillary thyroid cancer. Endocrine-Related Cancer 15 183-190. (doi:10.1677/ERC-07-0182)
120. Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, Kiuchi T & Murata Y 2009 Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocrine Journal 56 407-414. (doi:10.1507/endocrj.K08E-329)
121. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, Saji M, Schuppert F, Broelsch CE, Ringel MD & Eng C 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. Journal of Clinical Endocrinology and Metabolism 90 2512-2521. (doi:10.1210/jc.2004-2028)
122. Whitfield ML, George LK, Grant GD & Perou CM 2006 Common markers of proliferation. Nature Reviews. Cancer 6 99-106. (doi:10. 1038/nrc1802)
123. Williams ED, Abrosimov A, Bogdanova T, Demidchik EP, Ito M, LiVolsi V, Lushnikov E, Rosai J, Sidorov Y, Tronko MD et al. 2004 Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. British Journal of Cancer 90 2219-2224. (doi:10. 1038/sj.bjc.6601860)
124. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH & Singh B 2002 Genome-wide appraisal of thyroid cancer progression. American Journal of Pathology 161 1549-1556. (doi:10.1016/S0002-9440(10) 64433-1)
125. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G et al. 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 90 6373-6379. (doi:10.1210/jc.2005-0987)
126. Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ & Shioda T 2000 The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. Journal of Biological Chemistry 275 8825-8834. (doi:10.1074/jbc.275.12.8825)
127. Yang Q, Ye ZY, Zhang JX, Tao HQ, Li SG & Zhao ZS 2010 Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anatomical Record 293 2012-2019. (doi:10.1002/ar.21071)
128. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y & Uchida K 2004 Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clinical Cancer Research 10 2035-2043. (doi:10.1158/1078-0432.CCR-0807-03)
129. Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, Pellegata N & Chapelle AL 2007 Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. International Journal of Cancer 121 767-775. (doi:10. 1002/ijc.22701)
130. Yousem SA, Nikiforova M & Nikiforov Y 2008 The histopathology of BRAF-V600E-mutated lung adenocarcinoma. American Journal of Surgical Pathology 32 1317-1321. (doi:10.1097/PAS.0b013e31816 597ca)
131. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH & Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. American Journal of Clinical Pathology 120 71-77. (doi:10.1309/ND8D9LAJTRCTG6QD)